Challenges and perspectives in the multidisciplinary management of well-differentiated lung neuroendocrine tumours: a case report

Tindara Franchina, Alessandro Russo, Giuseppina RR Ricciardi, Vincenzo Adamo

Abstract


Neuroendocrine tumours of the lung represent a distinct subgroup of primary lung neoplasms, characterized by particular morphologic, ultrastructural, immunohistochemical and molecular peculiarities and different biological behavior. A detailed pathological diagnosis including immunohistochemistry, Ki-67, mitotic rate and necrosis status can be helpful to identify the different subtypes. The optimal management of advanced well-differentiated lung neuroendocrine tumors is still debated and can be very challenging for the clinician. Currently, no established therapeutic algorithm exists for patients with unresectable or metastatic typical carcinoids and atypical carcinoids. To highlight the importance of a multidisciplinary management we report the case of a patient affected by unresectable lung neuroendocrine tumors, who has benefited from integration strategy, resulting in complete surgical excision of the tumour.


Keywords


Neuroendocrine tumours; carcinoids; multidisciplinary management

Full Text:

PDF

References


Wolin, E.M., (2015) Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. Oncologist, 20(10),1123-31.

Travis,W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H., Beasley, M.B., Chirieac, L.R., Dacic, S., Duhig, E., Flieder, D.B., Geisinger, K., Hirsch, F.R., Ishikawa, Y., Kerr, K.M., Noguchi, M., Pelosi, G., Powell, C.A., Tsao, M.S., Wistuba, I., Panel, W.H. (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol, 10(9),1243-60.

Pelosi, G, Rodriguez, J., Viale, G., Rosai, J. (2005) Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol, 29(2),179-87.

Filosso, P.L., Ferolla, P., Guerrera, F., Ruffini, E., Travis, W.D., Rossi, G., Lausi, P.O., Oliaro, A. European Society of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering Committee. (2015) Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis, 7(Suppl 2),S163-71

Caplin, M.E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R.E., Travis, W.D. ENETS consensus conference participants. (2015) Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol, 26(8):1604-20.

Gridelli, C., Rossi, A., Airoma, G., Bianco, R., Costanzo, R., Daniele, B., Chiara, G.D., Grimaldi, G., Irtelli, L., Maione, P., Morabito, A., Piantedosi, F.V., Riccardi, F. (2013) Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev, 39(5),466-72.

Derks, J.L., van Suylen, R.J., Thunnissen, E., den Bakker, M.A., Smit, E.F., Groen, H.J., Speel, E.J., Dingemans, A.M. (2016) A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors. J Thorac Oncol, 11(4):593-602.

Pelosi, G., Rindi, G., Travis, W.D., Papotti, M., (2014) Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol, 9(3),273-84.

Yao, J.C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H, Voi, M., Pacaud, L.B., Rouyrre, N., Sachs, C., Valle, J.W., Delle Fave, G., Van Cutsem, E., Tesselaar, M., Shimada, Y., Oh, D.Y., Strosberg, J., Kulke, M.H., Pavel, M.E.; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968-77.

Ferolla, P., Brizzi, M.P., Meyer, T., Mansoor, W., Mazieres, J., Cao, C.D., Lena, H., Berruti, A., Damiano, V., Buikhuisen, W., Stankovic, M., Singh, N., Chiodini, E., Gislimberti , G. , Oberg, K., Baudin E. (2016) Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study. Ann Oncol, 27 (Supplement 6), vi136–vi148




DOI: https://doi.org/10.6092/1828-6550/APMB.105.1.2017.A3

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Tindara Franchina, Alessandro Russo, Giuseppina RR Ricciardi, Vincenzo Adamo

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.